Clinical Trial Update: Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial update of an allogeneic mixed chimerism stem cell transplant using Campath (alemtuzumab) for hemoglobinopathies and bone marrow failure syndromes;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Paroxysmal Nocturnal Hemoglobinuria
• Pure Red Cell Aplasia
• Sickle Cell Disease

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)

Snippet

Sponsor: David Rizzieri, MD | Conditions: Sickle Cell Anemia, Severe Aplastic Anemia | Phase 2 | Status: COMPLETED | Results posted: 2013-11-11